This study investigates the cross-reactivity of commercial BNP and NT-proBNP assays to clarify potential sources of confusion in clinical heart failure monitoring.
Answers are grounded in this paper and cite their sources.
May affect BNP/NT-proBNP interpretation in HF; leaves open assay standardization pending quantitative cross-reactivity data.
B-type natriuretic peptide (BNP) is a 32 amino acid cardiacsynthesized hormone that reduces blood pressure and increases sodium excretion (1 ). Following proteolytic cleavage of proBNP, a 108-amino acid precursor, an Nterminal fragment (NT-proBNP) and BNP are released (2 ). Increased concentrations of BNP and NT-proBNP can be used clinically to monitor heart failure, but a lack of alignment between commercial BNP and NT-proBNP assays (3 ) can lead to confusion when clinicians or laboratorians compare results measured for the same analyte on different instruments. Some of this confusion arises from variable assay specificity regarding what peptides are being measured. We studied whether (a) BNP assays demonstrated crossreactivity with NT-proBNP or proBNP, and (b) whether NT-proBNP assays demonstrated crossreactivity with BNP or proBNP, by using 5 commercial BNP and 3 commercial NT-proBNP assays
No takes yet. Share an insight, caveat, or question.
Luckenbill et al. (2008) studied Heart failure. Commercial BNP and NT-proBNP assays was evaluated on Cross-reactivity of BNP, NT-proBNP, and proBNP.
Synapse has enriched 10 related papers. Consider them for comparative context: